---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-199158"
form_type: "8-K"
ticker: "ANNX"
cik: "0001528115"
company_name: "Annexon, Inc."
filed_at: "2023-07-31T23:59:59+00:00"
generated_at: "2026-06-12T21:58:20.390697+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Annexon appoints Jamie Dananberg as CMO; ARCHER trial shows ANX007 vision protection in GA

## Summary
- Jamie Dananberg, M.D., appointed chief medical officer; previously CMO at UNITY Biotechnology and exec at Takeda and Eli Lilly.
- ARCHER Phase 2 trial in geographic atrophy showed ANX007 provided dose-dependent, statistically significant protection from vision loss (BCVA ≥15 letters).
- Primary endpoint of GA lesion growth rate did not reach significance; additional analyses show trend toward greater effect in second six months.
- ANX007 was well-tolerated with no increase in CNV or retinal vasculitis; company to discuss regulatory path with FDA later this year.
- Fellow-eye analysis showed 74% (monthly) and 47% (every-other-month) reduction in BCVA loss vs sham; off-treatment data support on-treatment benefit.

## SEC filing metadata
- accession: 0001193125-23-199158
- form_type: 8-K
- ticker: ANNX
- cik: 0001528115
- company_name: Annexon, Inc.
- filed_at: 2023-07-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1528115/000119312523199158/0001193125-23-199158-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1528115/000119312523199158/d418528d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-199158
- JSON: https://secwatch.observer/filing/0001193125-23-199158.json
- Plain text: https://secwatch.observer/filing/0001193125-23-199158.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.